RxDoctor Payments Data

Kristina Jones-Parker

Nurse Practitioner · Fayetteville, NCNPI 1063757144

Payments from drug & device makers

$597in general payments, 2019–2025

Across 14 payments — averaging $42.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$208
  • Avanir Pharmaceuticals, Inc.$114
  • Xeris Pharmaceuticals, Inc.$93
  • Lilly USA, LLC$85
  • Neurocrine Biosciences, Inc.$39
  • Exact Sciences$38
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$597100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$597 in reported general payments places this provider in the 70th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$67,364
Medicare patients
207
Services billed
1,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide89$93,414
EliquisApixaban123$68,065
TradjentaLinagliptin73$38,894
JanuviaSitagliptin Phosphate64$36,692
OzempicSemaglutide32$33,201
MyrbetriqMirabegron69$32,222
RexultiBrexpiprazole19$26,679
JardianceEmpagliflozin43$25,795
Incruse ElliptaUmeclidinium Bromide63$23,726
XareltoRivaroxaban33$19,609
FarxigaDapagliflozin Propanediol30$18,240
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc137$14,432
Tresiba Flextouch U-100Insulin Degludec39$14,308
LinzessLinaclotide25$14,281
Atorvastatin Calcium692$11,663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$85$93,41489 claims
Otsuka America Pharmaceutical, Inc.Rexulti$19$26,67919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →